Toshifumi Hibi

17PUBLICATIONS
55CO-AUTHORS
Molecular targetsPredictive and prognostic markersPacific Peoples cultural determinants of healthImmunogenetics (incl. genetic immunology)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 24, 2026
Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study.

Katsuyoshi Matsuoka, Erina Hata, Toshihiko Kaise

|May 15, 2025
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study.

Tadakazu Hisamatsu, Taku Kobayashi, Satoshi Motoya

|Feb 27, 2025
Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn's Disease: Results from the Japanese CONFIDE Study.

Toshifumi Hibi, Taku Kobayashi, Masaru Tanaka

|Dec 06, 2024
Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease.

Moeko Komatsu, Shintaro Sagami, Aya Hojo

|Oct 25, 2024
Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study.

Stefan Schreiber, Brian G Feagan, Edouard Louis

|Oct 16, 2024
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet's Disease: A Post-Marketing Surveillance.

Toshifumi Hibi, Shunsei Hirohata, Tadakazu Hisamatsu

Pageof 3

Frequent Collaborators

7 joint publications

Taku Kobayashi

5 joint publications

Katsuyoshi Matsuoka

5 joint publications

Tadakazu Hisamatsu

4 joint publications

Shintaro Sagami